About this trial
Acute radiation dermatitis (ARD) is almost universally experienced by patients with cancer during or after radiation therapy. This condition potentially leads to detrimental clinical outcomes as it adversely affects adherence to prescribed subsequent management and further worsens quality of life. Nevertheless, there remains no consensus on the appropriate intervention for ARD. This pilot two parallel-group randomized trial aims to clinically assess the potential of bacterial cellulose-monolaurin hydrogel, compared to placebo cream, to prevent high-grade ARD among Filipinos with breast cancer up to four weeks after last radiotherapy session.
Eligibility criteria
Qualifiers
Female sex at birth
Age at least 18 years at the time of invitation
Eastern Cooperative Oncology Group (ECOG) Performance Status score of either 0 or 1
With histopathologic diagnosis of breast carcinoma
Disqualifiers
Pregnant or lactating
With concurrent or previous history of any malignancy
With history of mediastinal or thoracic irradiation
With current bilateral synchronous breast carcinoma
Trial design
Treatments tested in this trial
- Bacterial cellulose-monolaurin hydrogel
- Placebo cream